Evidence map›Paper›PMID 37432466›Full record

ArticleArchives of dermatological research2023

Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.

M E Jacobson, K S Thomas, C J Apfelbacher, Y A Leshem, H C Williams, L A A Gerbens, P I Spuls, J Schmitt, L Howells, N Katoh and 2 more

Abstract readConference Proceedings
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M E JacobsonDepartment of Dermatology, Oregon Health and Science University, 3303 S. Bond Avenue, Portland, Oregon, 97239, USA.
K S ThomasCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
C J ApfelbacherInstitute of Social Medicine and Health Systems Research, Ottovon Guericke University Magdeburg, Magdeburg, Germany.
Y A LeshemDivision of Dermatology, Rabin Medical Center, Petach-Tikva, Israel.
H C WilliamsCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
L A A GerbensDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, The Netherlands.
P I SpulsDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, The Netherlands.
J SchmittCenter for Evidence-Based Healthcare, Medical Faculty Carl Gustav Carus, Dresden, Germany.
L HowellsCentre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.
N KatohDepartment of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
E L SimpsonDepartment of Dermatology, Oregon Health and Science University, 3303 S. Bond Avenue, Portland, Oregon, 97239, USA. simpsone@ohsu.edu.
Harmonising Outcome Measures for Eczema (HOME) Initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Harmonising Outcome Measures for Eczema (HOME) initiative established a core outcome set (COS) for atopic eczema (AE) clinical trials in 2019. This set encompasses four core outcome domains and corresponding measurement instruments: clinical signs (EASI), patient-reported symptoms (POEM and NRS 11 point for worst itch over the last 24 h), quality of life (DLQI/CDLQI/IDQoLI), and long-term control (Recap or ADCT). Following its roadmap, the HOME initiative is now focused on supporting implementation of the COS. To identify barriers and facilitators to implementation of the COS, and to guide the effort to promote COS uptake, a virtual consensus meeting was held over 2 days (September 25-26, 2021) attended by 55 participants (26 healthcare professionals, 16 methodologists, 5 patients, 4 industry representatives, and 4 students). Implementation themes were identified by a pre-meeting survey distributed to HOME members, presentations, and whole-group discussion. Participants were divided into five multi-professional small groups which ranked their top 3 most important themes, followed by whole-group discussion and anonymous consensus voting (consensus criteria: < 30% disagreement). Three most important implementation themes were identified and agreed upon: (1) awareness and stakeholder engagement, (2) universal applicability of the COS, and (3) ensuring minimum administrative burden. Working groups to address these issues are now a priority for the HOME initiative. The results from this meeting will inform the development of a HOME Implementation Roadmap in an effort to support other COS groups planning for effective implementation of their core sets.

Indexed as

Dermatitis, AtopicEczemaClinical Trials as TopicHumansOutcome Assessment, Health CareQuality of LifeResearch DesignSeverity of Illness IndexTreatment OutcomeAtopic eczemaCore outcome set implementationCore outcome setsHarmonising outcome measures for eczema initiative

Identifiers

PMID37432466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.